Abstract 1980: Identification of the transcription factor ZNF217 in ER+ subset of BC: A functional relationship with the PI3K-AKT-mTOR pathway
Nandini Dey(University of South Dakota), Brian Leyland‐Jones(Avera Health), Benjamin Solomon(Peter MacCallum Cancer Centre), Kirstin Williams(Avera Health), Luis A. Rojas(Institut de Seguretat Pública de Catalunya), David Starks(Cleveland Clinic), Timea Metzger-Nelson(Avera Health), Casey Williams(Avera Health), Mark Abramovitz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yuliang Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Jennifer Carlson(Avera Health), Pradip De(University of South Dakota), Xiaoqian Lin(Chinese Academy of Sciences), Jessica Klein(Cancer Institute (WIA)), Amy Krie(Amgen (United States))
Cited by 0
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k